GILD - Gilead Sciences, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
67.42
-0.11 (-0.16%)
As of 1:02PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close67.53
Open67.65
Bid67.51 x 900
Ask67.51 x 1100
Day's Range67.00 - 67.93
52 Week Range63.76 - 89.54
Volume2,202,959
Avg. Volume7,199,711
Market Cap87.664B
Beta1.35
PE Ratio (TTM)25.64
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield2.28 (3.49%)
Ex-Dividend Date2018-06-14
1y Target EstN/A
Trade prices are not sourced from all markets
  • Final Trade: IBB, GILD & more
    CNBC Videos14 days ago

    Final Trade: IBB, GILD & more

    The "Fast Money" traders share their final trades of the day, including Ethereum, Match, the IBB and Gilead.

  • You should know the cost of a drug or procedure before it...
    CNBC Videos14 days ago

    You should know the cost of a drug or procedure before it...

    Sen. Bill Cassidy (R-La.) discusses Trump's plan to lower drug prices.

  • How Ionis’s Spinraza Did in Q1
    Market Realist4 hours ago

    How Ionis’s Spinraza Did in Q1

    Ionis Pharmaceuticals’ (IONS) Spinraza (nusinersen) is an FDA-approved drug designed for the treatment of spinal muscular atrophy, a type of severe motor-neuron disease in pediatric patients and adults. Biogen (BIIB), which has held the worldwide development and commercialization rights for Spinraza since January 2012, forwards royalties to Ionis.

  • ETF Trendsyesterday

    Will “Right to Try” Bill Boost Biotech ETFs?

    The iShares Nasdaq Biotechnology ETF (NASDAQGM: IBB) , the largest biotech exchange traded fund by assets, and other biotechnology assets traded slightly higher Wednesday after the U.S. House of Representatives on Tuesday passed “right to try” legislation. IBB tracks the Nasdaq Biotechnology Index and holds nearly 160 stocks.

  • He helped Gilead score billions from HIV, hepatitis C drugs — now he's building a cancer fighter
    American City Business Journals2 days ago

    He helped Gilead score billions from HIV, hepatitis C drugs — now he's building a cancer fighter

    During his tenure at Gilead, Norbert Bischofberger saw employment go from 25 or so to 10,000 as the company cranked up life-changing drugs fighting HIV and hepatitis C. Now he wants to build again, and Gilead Chairman John Martin is coming along, too.

  • How Are Tesaro’s Valuations and Cash Flows?
    Market Realist3 days ago

    How Are Tesaro’s Valuations and Cash Flows?

    Tesaro used $147.6 million in operating activities in the first quarter—compared to $114.6 million in the first quarter of 2017. The company used $1.6 million in investing activities in the first quarter—compared to $1.8 million in the first quarter of 2017. The expense was mainly for purchasing property and equipment related to Tesaro expanding leased premises at its headquarters.

  • Tesaro Stock: What’s the Upside Potential?
    Market Realist3 days ago

    Tesaro Stock: What’s the Upside Potential?

    Tesaro (TSRO) is a commercial stage biopharmaceutical company focused on developing treatments for solid tumors. Tesaro is licensed and developing a number of oncology-related product candidates. Of the 19 analysts covering Tesaro in May, 12 analysts gave the stock a “buy” or higher rating, while seven analysts gave a “hold” rating.

  • Gauging the Upside Potential of Vertex Pharmaceuticals Stock
    Market Realist3 days ago

    Gauging the Upside Potential of Vertex Pharmaceuticals Stock

    Vertex Pharmaceuticals (VRTX) is focused on developing and bringing to market therapies for treating cystic fibrosis (or CF) and advancing research and development programs for other diseases. Of the 25 analysts covering Vertex Pharmaceuticals in May, 21 of them have given the stock a “buy” or higher rating, and four have given it a “hold.” The mean rating for the stock is 1.76 with a target price of $191.39, implying an upside of 22.6% over its closing price of $156.16 on May 16. Of the 26 analysts covering Gilead Sciences (GILD) in May, 16 of them have given the stock a “buy” or higher rating, and ten have given it a “hold.” The mean rating for the stock is 2.15 with a target price of $85.81.

  • Roche’s Blockbuster Drug: Rituxan and Avastin in Q1 2018
    Market Realist3 days ago

    Roche’s Blockbuster Drug: Rituxan and Avastin in Q1 2018

    Roche’s (RHHBY) MabThera/Rituxan reported revenues of 1.7 billion Swiss francs in the first quarter compared to 1.9 billion Swiss francs in the first quarter of 2017, which reflected a decline of ~8% YoY (year-over-year) on constant exchange rate basis.

  • What Led to MEI Pharma Stock’s 55% Rise Last Week?
    Market Realist3 days ago

    What Led to MEI Pharma Stock’s 55% Rise Last Week?

    MEI Pharma (MEIP) saw a 55% rise in its stock price between May 11 and May 18. On May 18, the stock closed at $3.46, a 119% increase from its 52-week low of $1.58 on May 19, 2017. On May 15, 2018, MEI Pharma stock closed at $3.40, a ~34.4% increase over the previous close of $2.53 on May 14, 2018. The stock rose ~58% in the last quarter. 

  • 3 Biotechs on the FDA's Naughty List That Should Be on Investors' Buy Lists
    Motley Fool3 days ago

    3 Biotechs on the FDA's Naughty List That Should Be on Investors' Buy Lists

    The FDA might be down on these biotechs, but investors shouldn't be.

  • FDA Shame List: 40 Drug Makers That Try to Block Generic Drugs
    InvestorPlace7 days ago

    FDA Shame List: 40 Drug Makers That Try to Block Generic Drugs

    The Food and Drug Administration (FDA) announced a shame list of companies that try to block generic drugs in order to ramp up profits.

  • Reuters7 days ago

    EU warns of possible birth defect link to GSK's HIV drug

    Europe's medicines regulator said it was assessing evidence that GlaxoSmithKline's successful HIV drug dolutegravir might be linked to birth defects, adding it should not be prescribed to women seeking to become pregnant. Friday's move by the European Medicines Agency follows preliminary data from a study in Botswana which found four cases of neural tube defects (NTDs), such as spina bifida, in babies born to mothers who became pregnant while taking the drug. Dolutegravir is a so-called integrase inhibitor found in the branded medicines Tivicay and Triumeq, which are sold by GSK's majority-owned ViiV Healthcare unit.

  • The FDA Is Trying To 'Shame' Celgene, Gilead — Here's Why It Won't Work
    Investor's Business Daily8 days ago

    The FDA Is Trying To 'Shame' Celgene, Gilead — Here's Why It Won't Work

    Celgene toppled to a four-year low Thursday after it appeared on a list from the FDA attempting to "shame" drugmakers working to block generic competition.

  • Gilead, BioMarin among Bay Area drug makers shamed by FDA in generics 'gaming' list
    American City Business Journals8 days ago

    Gilead, BioMarin among Bay Area drug makers shamed by FDA in generics 'gaming' list

    Opening another front in President Donald Trump's war on drug prices, the FDA releases a list of companies "gaming" the system to delay lower-priced generics from getting to market.

  • Sangamo Therapeutics Stock History
    Motley Fool8 days ago

    Sangamo Therapeutics Stock History

    After decades of research into gene editing, this biotech company could be on the cusp of developing game-changing new treatments for rare diseases.

  • Taking Stock of Gilead Sciences’ Key Developments
    Market Realist8 days ago

    Taking Stock of Gilead Sciences’ Key Developments

    During the first quarter, Gilead Sciences (GILD) entered into a scientific collaboration with Verily Life Sciences to identify and better understand the immunological basis of three common, serious inflammatory diseases—rheumatoid arthritis, inflammatory bowel disease, and lupus-related diseases—by making use of Verily’s Immunoscape platform.

  • Reuters8 days ago

    FDA names drugmakers likely blocking access to branded drug samples

    The U.S. Food and Drug Administration on Thursday named drugmakers including Celgene Corp, Mylan NV, Gilead Sciences and Novartis AG for potentially blocking access to samples of their products to delay generic competition. Generic drugmakers may not be able to develop alternatives without access to samples of branded products, the FDA said. The regulator said it had heard of some brand companies adopting tactics to make it hard for the generic companies to purchase branded drugs at a fair value and in open market.

  • 3 High-Yield Stocks With Virtual Monopolies
    Motley Fool8 days ago

    3 High-Yield Stocks With Virtual Monopolies

    This trio of high-yield stocks offers dividend investors a lock on key markets with virtual monopolies driving big dividend payments.

  • Gilead Sciences’ Cash Flows, Valuations, and Price Performance
    Market Realist8 days ago

    Gilead Sciences’ Cash Flows, Valuations, and Price Performance

    Gilead Sciences (GILD) stock has corrected 9.6% since the start of 2018 to close at $66.99 on May 15. In comparison, Johnson & Johnson (JNJ), Pfizer (PFE), and Merck & Co. (MRK) have returned -9.5%, -2.1%, and 5.3%, respectively.

  • A Look at Gilead Sciences’ Financial Performance
    Market Realist8 days ago

    A Look at Gilead Sciences’ Financial Performance

    Gilead Sciences’ (GILD) total revenues decreased from $6.5 billion in Q1 2017 to $5.1 billion in Q1 2018, primarily due to lower product sales. The company earns a small part of its revenues from royalty, contract, and other sources. While product sales were $6.3 billion in Q1 2017 and $5 billion in Q1 2018, royalty, contract, and other revenues were $128 million in Q1 2017 and $87 million in Q1 2018.

  • Gilead Sciences’ Product Performance: A Mixed Bag in Q1 2018
    Market Realist9 days ago

    Gilead Sciences’ Product Performance: A Mixed Bag in Q1 2018

    In the first quarter, Gilead Sciences’ (GILD) total product sales decreased to $5 billion from $6.3 billion in the first quarter of 2017. For fiscal 2018 and fiscal 2019, it’s expected to report total revenues of $20.8 billion and $21.1 billion, respectively.

  • Gilead Sciences Stock: How Much Upside Do Analysts Expect?
    Market Realist9 days ago

    Gilead Sciences Stock: How Much Upside Do Analysts Expect?

    Gilead Sciences (GILD) is a research-based biopharmaceutical company focused on discovering, developing, and bringing to market innovative medicines for life-threatening diseases. Gilead released its first-quarter earnings on May 4. Of the 26 analysts covering Gilead Sciences stock in May, 16 of them have given the stock a “buy” or higher rating, and ten have given it a “hold.” The mean rating for the stock is 2.2 with a target price of $85.81, which implies an upside potential of 27.2% over its closing price of $66.99 on May 15.

  • Breakout Watch: Biotech Stock With 172% Growth Enters Buy Zone
    Investor's Business Daily9 days ago

    Breakout Watch: Biotech Stock With 172% Growth Enters Buy Zone

    Leading biotech stock and IBD 50 member Ligand Pharmaceuticals is in a buy zone after reporting 172% earnings growth.

  • MarketWatch11 days ago

    Why Trump’s drug-price pitch makes no sense

    Donald Trump’s speech on drug prices on Friday was no surprise — it was his usual mishmash of pseudo-populist nonsense, obscuring the standard-issue corporatist Republican agenda he reverts to when he knows nothing, which is most of the time. The speech abandoned one of the few more-or-less populist campaign promises the president made in 2016 — to have Medicare begin negotiating over drug prices, reversing a law his party passed specifically to maximize drug-company profits.